Literature DB >> 1911345

Red cell ABO incompatibility and production of tumour necrosis factor-alpha.

R D Davenport1, R M Strieter, S L Kunkel.   

Abstract

Tumour necrosis factor-alpha (TNF) is a major mediator of diverse pathophysiological events similar to those of haemolytic transfusion reactions (HTR), such as fever, intravascular coagulation and organ failure. However, the possible role of TNF in HTR has not been investigated. We have constructed an in vitro whole blood model of HTR to examine whether TNF may be produced in red cell ABO incompatibility. TNF was observed in plasma, in a dose dependent manner, when ABO incompatible red cells were added, but not with compatible (group O) cells. Plasma TNF levels were maximal at 2 h, and declined to control levels by 24 h. Haemolysis of incompatible red cells was accompanied by TNF production. Immune haemolysis induced TNF gene expression by buffy coat leucocytes, as determined by Northern blot analysis. Heat inactivation of plasma abolished TNF production, whereas prior treatment with interferon-gamma augmented the response. These results demonstrate that a major cytokine is produced in response to red cell incompatibility, and suggest that TNF may play a role in the pathogenesis of haemolytic transfusion reactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911345     DOI: 10.1111/j.1365-2141.1991.tb04485.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange.

Authors:  Burak Deveci; Rabin Saba; Husnu Altunay; Tayfur Toptas; George Kublashvilli; Ihsan Karadogan
Journal:  Transfus Med Hemother       Date:  2021-01-08       Impact factor: 3.747

2.  A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration.

Authors:  Akio Namikawa; Yuko Shibuya; Haruki Ouchi; Hiroko Takahashi; Yoshitaka Furuto
Journal:  CEN Case Rep       Date:  2018-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.